迈阿密讯 - 专注于其专有CellFX纳秒脉冲场消融（nsPFA）技术的生物电子医疗公司Pulse Biosciences, Inc. (NASDAQ: PLSE)宣布，任命Jon Skinner为新任首席财务官，即日起生效。此次领导层扩充旨在加强公司的运营卓越性和其CellFX ...

Pulse Biosciences, Inc. (Nasdaq: PLSE) (the "Company" or "Pulse Biosciences"), a company leveraging its novel and proprietary ...

Pulse Biosciences (Nasaq:PLSE) announced today that it appointed Jon Skinner as CFO, effective Feb. 3, 2025.

Pulse Biosciences, Inc. (PLSE), a novel bioelectric medicine company, Tuesday announced the appointment of Jon Skinner as Chief ...

Pulse Biosciences (PLSE) announced the appointment of Jon Skinner as Chief Financial Officer, effective February 3. “I am excited to announce ...

Pulse Biosciences has hired Jon Skinner as the bioelectric medicine company's new chief financial officer. Pulse on Tuesday said Skinner most recently served as vice president of financial planning ...

MIAMI - Pulse Biosciences, Inc. (NASDAQ: NASDAQ:PLSE), a bioelectric medicine company focusing on its proprietary CellFX nanosecond Pulsed Field Ablation (nsPFA) technology, has announced the ...

Pulse Biosciences, Inc. (NASDAQ: PLSE) announced the appointment of Jon Skinner as the company’s Chief Financial Officer (CFO), effective February 3, 2025. Alongside his role as CFO, Mr. Skinner will ...

Already cleared in the US for use in soft tissue ablation, Pulse Biosciences is looking to add AF to CellFX’s indication list.

Pulse Biosciences today announced feasibility study data supporting its Nanosecond PFA 360° cardiac catheter system.

MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the late ...

MIAMI, January 10, 2025--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the "Company" or "Pulse Biosciences"), a company leveraging its novel and proprietary Nanosecond Pulsed Field ...